The TNFRSF13B rs34562254 Polymorphism is Associated with Hepatitis C Infection Risk in the Han Chinese Population

Haozhi Fan  
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Zuqiang Fu  
Nanjing Medical University

Zhijun Ge  
Affiliated Yixing Hospital of Jiangsu University

Chen Dong  
Soochow University Medical College

Chunhui Wang  
Eastern Theater Command Centers for Disease Control and Prevention

Chao Shen  
Nanjing Medical University

Jun Li  
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Rongbin Yu  
Nanjing Medical University

Yun Zhang  
Nanjing Medical University

Ming Yue  (✉ yueming@njmu.edu.cn)  
Nanjing Medical University

Research article

Keywords:

DOI: https://doi.org/10.21203/rs.3.rs-147629/v1

License: ☇️ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background

Genetic variations in the tumor necrosis factor receptor superfamily (TNFRSF) 13B have been reported to be associated with immune-related diseases. This study aimed to explore the relationship of tumor necrosis factor superfamily (TNFSF) 13, TNFRSF13B, and TNFRSF14 missense mutations with hepatitis C virus (HCV) infection susceptibility.

Methods

Single-nucleotide polymorphisms (SNPs) in TNFSF13 (rs3803800, rs11552708), TNFRSF13B (rs34562254), and TNFRSF14 (rs4870) were genotyped in 469 intravenous drug users, 728 hemodialysis patients, and 1636 paid blood donors using a TaqMan real-time PCR assay. The USCS browser and RNAfold web servers were used to predict the biological functions of these selected SNPs.

Results

After adjusting for gender, age, levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and route of infection, a logistic regression analysis showed that subjects carrying a homozygous TNFRSF13B rs34562254 TT mutant were more likely to be infected by HCV compared to those homozygous with the rs34562254 CC wild type (co-dominant model: OR = 1.52, 95% CI: 1.17–1.98, P = 0.002; recession model: OR = 1.41, 95% CI: 1.10–1.81, P = 0.007; additive model: OR = 1.21, 95% CI: 1.07–1.37, P = 0.002). The effect of the risk allele rs34562254-T was stronger in subjects that were female, older (≥ 50 years old), paid blood donors, and with lower ALT and AST levels (≤ 40 U/L). A bioinformatics analysis via the UCSC genome browser found that rs34562254 was located at the highest peak of the H3K4Me1 histone marker. Using the RNAfold web servers, the minimum free energy of the centroid secondary structure was found to be higher for the mutant rs34562254-T allele (-38.90 kcal/mol) than its wild type C allele (-45.60 kcal/mol). Additionally, the RegulomeDB score of rs34562254 was 3a. Altogether, the results of the bioinformatics analysis indicate that rs34562254 may affect gene expression levels by regulating the transcriptional activity of corresponding gene regions.

Conclusions

The rs34562254 polymorphisms in TNFRSF13B were significantly associated with HCV infection among the Han Chinese population.

Background
The hepatitis C virus (HCV) is a positive-strand RNA virus mainly transmitted through exposure to blood, for example, via blood transfusion or reuse of contaminated medical equipment. Currently, more than 70 million people are estimated to be chronically infected with HCV \[^{1,2}\] which often leads to chronic hepatitis, liver failure, and hepatocellular carcinoma \[^{3-5}\]. Despite the development of direct-acting antivirals (DAAs) over the last decade, reinfection after successful treatment remains a problem in people who engage in risky behavior. Additionally, a vaccine that effectively prevents HCV infection is not yet currently available \[^{6,7}\]. Therefore, the factors affecting HCV infection outcomes are a critical issue and require further research.

It is well known that the progression of HCV infection is mainly affected by its biological characteristics, the host's immunity and genetic background, and the environment \[^{8}\]. Among these factors, the immune system is generally recognized as an essential determinant of viral infection outcome \[^{9,10}\]. The tumor necrosis factor receptor superfamily (TNFRSF), is naturally activated by members of the tumor necrosis factor superfamily (TNFSF), consists of 29 members in humans, and is mostly expressed in the immune system \[^{11-13}\]. Previous studies have reported that TNFSF/TNFRSF significantly affects the development of numerous diseases, such as rheumatoid arthritis \[^{14}\], inflammatory bowel disease \[^{15}\], and multiple sclerosis \[^{16}\]. Therefore, we hypothesize that TNFSF/TNFRSF, by regulating the immune response, can affect HCV infection outcome.

We previously reported that genetic variants of TNFSF/TNFRSF such as TNFRSF1A \[^{17}\], TNFRSF5 \[^{18}\], TNFSF6 \[^{19}\], and TNFRSF11B \[^{20}\] influence the immune response to HCV infection and are associated with various immune-related diseases. In addition, several studies have reported that genetic mutations of TNFSF13, TNFRSF13B, and TNFRSF14 are significantly associated with immune-related diseases including chronic lymphocytic leukemia \[^{21}\], IgA deficiency \[^{22}\], systemic lupus erythematosus (SLE) \[^{23}\], asthma \[^{24}\], familial or sporadic immune thrombocytopenia, and common variable immunodeficiency (CVID) \[^{22,25}\]. Thus, this study mainly focused on the association between single nucleotide polymorphisms (SNPs) in TNFSF13, TNFRSF13B, and TNFRSF14 and HCV infection outcomes. More specifically, we assayed the TNFSF13 rs3803800, TNFSF13 rs11552708, TNFRSF13B rs34562254, and TNFRSF14 rs4870 polymorphisms in 2833 Chinese adults at high-risk of HCV infection and subsequently analyzed the association between these variants and HCV infection.

### Methods

### Participants

2833 Chinese adults (18–80 years old) from three high-risk groups (intravenous drug users, IVDU; hemodialysis patients, HD; and paid blood donors, PBD) were assayed. Data from the subjects were collected between 2008 to 2016 from three different centers: the Nanjing Compulsory Drug Rehabilitation Center in Jiangsu province (IVDU; \(n = 459\)), nine hospital hemodialysis centers in southern China (HD; \(n = 722\)), and paid blood donors from six villages in Zhenjiang (PBD; \(n = 1619\)). Each participant underwent structured interviews and answered standardized questionnaires for demographic information and
environmental exposure histories. Subjects co-infected with other hepatotropic viruses or with human immunodeficiency virus (HIV), who suffered from other liver diseases, or received any antiviral therapy were excluded from the study.

Structured interviews and standardized questionnaires were carried out with every participant to obtain demographic and environmental exposure history information. When exposed to HCV, some people may become infected by the virus and carry seropositive anti-HCV. Only 30% of these newly infected people can effectively clear the virus; that is, they carry seropositive anti-HCV and seronegative HCV RNA. Those who fail to clear HCV within 6 months will develop chronic HCV infection and carry seropositive anti-HCV and seropositive HCV RNA \[^{26, 27}\]. From these distinctions \[^{27}\], participants were assigned to three groups based on the state of their sera HCV antibody and sera HCV RNA. In Group A, the HCV uninfected control group, subjects carried seronegative anti-HCV and seronegative HCV RNA. Those who carried seropositive anti-HCV and seronegative HCV RNA formed the HCV spontaneous clearance group (Group B). Finally, subjects who carried seropositive anti-HCV and seropositive HCV RNA were classified into the HCV chronic infection group (Group C). Additionally, the HCV spontaneous clearance group (Group B) and HCV chronic infection group (Group C) were combined into a case group (Group B + C) and compared to the HCV uninfected control group (Group A). Thus, we compared genotype frequencies between Group A and Group (B + C) to explore the association between candidate SNPs and/or other risk factors to the susceptibility of HCV infection. We also compared genotype frequencies between Group B and Group C to determine whether candidate SNPs and/or other risk factors associate with chronic HCV infection.

**Serological testing**

10 mL of venous blood collected in anticoagulative EDTA tubes was taken from the subjects. The plasma, white blood cells, and red blood cells were centrifuged and stored at -20 °C for later examination. Anti-HCV, viral load and genotype, HBV/HIV serological markers, and biochemical indicators of liver function (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) were measured using commercial reagents according to the manufacturers’ instructions.

**SNPs selection**

Genetic information regarding the \(TNFSF13\), \(TNFRSF13B\), and \(TNFRSF14\) genes from HapMap (Phase II; CHB, Han Chinese in Beijing; upwards of 2 kb upstream and downstream) were downloaded from the 1000 Genomes database (http://www.1000genomes.org/). To extract their corresponding tagSNPs, we loaded the data into Haploview 4.2 software and set the minor allele frequency (MAF) as > 0.05 and correlation coefficient \(r^2\) as ≥ 0.8. Furthermore, we used the HaploReg database (https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php) and SNP Function Prediction (https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html) to select four missense mutation SNP candidates (rs3803800, rs11552708, rs34562254, and rs4870) for analysis.

**SNPs genotyping**

Genomic DNA was extracted from venous blood using the phenol-chloroform method. DNA purity and concentration were determined with ultraviolet spectrophotometry, standardized, and stored at -20°C.
Results

Participant characteristics

Based on their anti-HCV and HCV RNA results, subjects were divided into three groups: HCV uninfected control group (Group A; \( n = 1543 \)), HCV spontaneous clearance group (Group B; \( n = 522 \)), and HCV chronic infection group (Group C; \( n = 758 \)). The demographic and clinical information for the three groups were shown in Table 1. The groups did not significantly differ in age or gender distributions (both \( P > 0.05 \)). However, ALT and AST levels, infection route, and distribution of HCV genotypes significantly differed among the three groups (both \( P < 0.05 \)).

In silico analysis

We used the following to analyze the biological functions of our selected SNPs: the RegulomeDB online database (http://www.regulomedb.org/) to obtain RegulomeDB scores representing regulatory potential (Table S2); Vienna RNA Web Servers (http://rna.tbi.univie.ac.at/cgi-bin/RNAWeb Suite/RNAfold.cgi; ViennaRNA Package Version 2.4.4) to predict secondary structures of single stranded RNA sequences; and the UCSC Genome Bioinformatics website (http://genome.ucsc.edu/) to elucidate potential biological functions. H3K4Me1 histone marker data from seven cell lines (GM12878, H1-hESC, HSMM, HUVEC, K562, NHEK, and NHLF) was also collected and analyzed.

Statistical analysis

For basic genetic information, a Hardy-Weinberg equilibrium (HWE) was estimated for each SNP among the control subjects (Group A) using a goodness-of-fit \( \chi^2 \) test. To compare demographic differences among the three groups, we used one-way analysis of variance (ANOVA), chi-square \( (\chi^2) \) test, or Kruskal-Wallis test where appropriate. The association between each SNP and HCV infection susceptibility or outcome was estimated by constructing logistic regression models based on age, gender, and route of infection. The associations were further clarified with odds ratios (ORs) and 95% confidence intervals (CIs) using co-dominant, dominant, recessive, and additive models.

STATA14.0 software was used to perform statistical analyses. \( P \)-values < 0.05 were considered significant in all analyses except in multiple comparisons between SNPs, in which after Bonferroni corrections, \( P \)-values < 0.0125 (0.05/4) were considered significant.

Results
Table 1
Demographic and clinical characteristics among HCV uninfected control, spontaneous clearance and chronic infection groups.

| Variables                  | Group A (%) | Group B (%) | Group C (%) | P      |
|----------------------------|-------------|-------------|-------------|--------|
| n                          | n = 1543    | n = 522     | n = 768     |        |
| Age (years)                | 53.2 ± 13.7 | 50.3 ± 14.1 | 51.9 ± 12.4 | < 0.001<sup>a</sup> |
| < 50                       | 561 (36.36) | 212 (40.61) | 312 (40.63) | 0.067<sup>b</sup> |
| ≥ 50                       | 982 (63.64) | 310 (59.39) | 456 (59.38) |        |
| Gender                     |             |             |             | 0.117<sup>b</sup> |
| Male                       | 617 (39.99) | 199 (38.12) | 273 (35.55) |        |
| Female                     | 926 (60.01) | 323 (61.88) | 495 (64.45) |        |
| ALT (U/L)                  |             |             |             | < 0.001<sup>b</sup> |
| ≤ 40                       | 1450 (94.96) | 416 (79.85) | 453 (59.14) |        |
| > 40                       | 77 (5.04)   | 105 (20.15) | 313 (40.86) |        |
| AST (U/L)                  |             |             |             | < 0.001<sup>b</sup> |
| ≤ 40                       | 1456 (95.48) | 424 (82.65) | 467 (61.69) |        |
| > 40                       | 69 (4.52)   | 89 (17.35)  | 290 (38.31) |        |
| Route of infection         |             |             |             | < 0.001<sup>b</sup> |
| HD                         | 561 (36.36) | 91 (17.43)  | 76 (9.90)   |        |
| IVDU                       | 181 (11.73) | 148 (28.35) | 140 (18.23) |        |
| PBD                        | 801 (51.91) | 283 (54.21) | 552 (71.88) |        |
| HCV genotype               |             |             |             | < 0.001<sup>b</sup> |
| 1b                         | –           | 42 (26.25)  | 223 (46.07) |        |
| Non-1b                     | –           | 118 (73.75) | 261 (53.93) |        |

Group A: uninfected controls; Group B: spontaneous clearance subjects; Group C: chronic infection patients.

Non-1b means viral strains other than 1b, including genotype 1a, 2, and 3 (either solely or mixed infection).

Abbreviations: HCV, hepatitis C virus; SD, standard deviation; ALT, alanine transaminase; AST, aspartate transaminase; HD, hemodialysis patients; IVDU, Intravenous drug user; PBD, paid blood donors.
Association of candidate SNPs with HCV infection outcomes

The MAFs of the selected SNPs were greater than 20%, and all of them were consistent with HWEs from the HCV uninfected group (Group A; Table S1). As shown in Table 2, after adjusting for age, gender, and other potential confounding factors, a logistic regression analysis found that participants carrying TNFRSF13B rs34562254-T had an increased risk of HCV infection (co-dominant model: OR = 1.52, 95% CI: 1.17–1.98, \( P = 0.002 \); additive model: OR = 1.21, 95% CI: 1.07–1.37, \( P = 0.002 \); recessive model: OR = 1.41, 95% CI = 1.10–1.81, \( P = 0.007 \)). However, we did not find an association between SNPs and HCV infection outcome (all \( P > 0.05 \)).
Table 2
Genotypes distributions of TNFRSF genes among HCV uninfected control, spontaneous clearance and chronic infection groups.

| SNPs (genotype) | Group A n (%) | Group B n (%) | Group C n (%) | OR(95%CI) | P | OR(95%CI) | P |
|-----------------|---------------|---------------|---------------|-----------|---|-----------|---|
| n = 1543        | n = 522       | n = 768       |               |           |   |           |   |
| TNFSF13-rs3803800 |               |               |               |           |   |           |   |
| GG              | 645 (44.00)   | 221 (43.50)   | 342 (46.22)   | 1.00      | – | 1.00      | – |
| GA              | 669 (45.63)   | 231 (45.47)   | 325 (43.92)   | 1.01 (0.85–1.21) | 0.908 | 0.91 (0.70–1.17) | 0.443 |
| AA              | 152 (10.37)   | 56 (11.02)    | 73 (9.86)     | 1.00 (0.74–1.33) | 0.977 | 0.85 (0.56–1.27) | 0.421 |
| Dominant model  |               |               |               | 1.01 (0.85–1.19) | 0.93 | 0.89 (0.70–1.14) | 0.361 |
| Recessive model |               |               |               | 1.00 (0.75–1.31) | 0.946 | 0.89 (0.60–1.31) | 0.550 |
| Additive model  |               |               |               | 1.00 (0.88–1.14) | 0.971 | 0.91 (0.76–1.10) | 0.334 |
| TNFSF13-rs11552708 |           |               |               |           |   |           |   |
| GG              | 573 (38.00)   | 183 (35.47)   | 249 (32.98)   | 1.00      | – | 1.00      | – |
| GA              | 684 (45.36)   | 252 (48.84)   | 390 (51.66)   | 1.18 (0.98–1.41) | 0.080 | 1.06 (0.814–1.370) | 0.680 |
| AA              | 251 (16.64)   | 81 (15.7)     | 116 (15.36)   | 0.91 (0.711–1.72) | 0.468 | 1.00 (0.698–1.440) | 0.991 |
| Dominant model  |               |               |               | 1.11 (0.93–1.31) | 0.257 | 1.04 (0.81–1.34) | 0.736 |
| Recessive model |               |               |               | 0.83 (0.66–1.04) | 0.112 | 0.97 (0.70–1.35) | 0.856 |
| Additive model  |               |               |               | 1.03 (0.92–1.15) | 0.615 | 1.05 (0.89–1.24) | 0.576 |
| TNFRSF13B-rs34562254 |         |               |               |           |   |           |   |
| CC              | 661 (43.95)   | 190 (36.54)   | 312 (41.16)   | 1.00      | – | 1.00      | – |
| CT              | 673 (44.75)   | 251 (48.27)   | 340 (44.85)   | 1.15 (0.96–1.38) | 0.119 | 0.81 (0.63–1.05) | 0.112 |
| SNPs (genotype) | Group A n (%) | Group B n (%) | Group C n (%) | OR(95%CI)\(^a\) | \(P^a\) | OR(95%CI)\(^b\) | \(P^b\) |
|----------------|--------------|--------------|--------------|----------------|--------|----------------|--------|
| TT | 170(11.30) | 79 (15.19) | 106 (13.98) | **1.52 (1.17–1.98)** | **0.002** | 0.86 (0.60–1.22) | 0.401 |
| Dominant model | | | | 1.22 (1.03–1.45) | 0.019 | 0.82 (0.65–1.05) | 0.114 |
| Recessive model | | | | **1.41 (1.10–1.81)** | **0.007** | 0.96 (0.69–1.34) | 0.805 |
| Additive model | | | | **1.21 (1.07–1.37)** | **0.002** | 0.90 (0.76–1.06) | 0.213 |
| **TNFRSF14-rs4870** | | | | | | | |
| AA | 455(29.88) | 177 (34.57) | 241 (31.84) | 1.00 | – | 1.00 | – |
| AG | 782 (51.35) | 236(46.09) | 352 (46.50) | 0.77 (0.64–0.93) | 0.043 | 1.06 (0.81–1.38) | 0.684 |
| GG | 286 (18.78) | 98 (19.34) | 164 (21.66) | 0.96(0.75–1.21) | 0.708 | 1.25 (0.90–1.74) | 0.186 |
| Dominant model | | | | 0.82 (0.69–0.98) | 0.028 | 1.11 (0.87–1.43) | 0.396 |
| Recessive model | | | | **1.12 (0.91–1.38)** | **0.290** | **1.21 (0.904–1.63)** | **0.201** |
| Additive model | | | | 0.95 (0.84–1.07) | 0.391 | 1.11(0.94–1.31) | 0.206 |

Abbreviations: CI, confidence interval; HCV, hepatitis C virus; OR, odds ratio; SNP, single nucleotide polymorphism.

Group A: uninfected controls; Group B: spontaneous clearance subjects; Group C: chronic infection patients.

*The \(P^a\) value of \(\chi^2\)-test refer to the distribution of SNPs between Group A and Group (B + C).

**The \(P^b\) value of \(\chi^2\)-test refer to the distribution of SNPs between Group B and Group C.

\(^a\)The \(P^a\) value, OR and 95% CIs of Group (B + C) versus Group A were calculated on the basis of the logistic regression model, adjusted by gender, age, ALT level, AST level and route of infection.

\(^b\)The \(P^b\) value, OR and 95% CIs of Group C versus Group B were calculated on the basis of the logistic regression model, adjusted by gender, age, ALT level, AST level and route of infection.

Bonferroni correction was applied and the \(P^a\) value was adjusted to 0.0125 (0.05/4).

Bold type indicates statistically significant results.

Stratification analysis of **TNFRSF13B rs34562254**
To further explore the rs34562254 loci, we used stratified analysis based on the additive model to exclude the influence of confounding factors. As shown in Table 3, the rs34562254 genotype remained significantly related to HCV susceptibility in the age and gender subgroups (both $P < 0.0125$). Additionally, other variables such as ALT $\leq 40$ U/L (OR = 1.22, 95% CI = 1.07–1.39, $P = 0.003$), AST $\leq 40$ U/L (OR = 1.23, 95% CI = 1.08–1.40, $P = 0.002$) and PBD (OR = 1.29, 95% CI = 1.09–1.53, $P = 0.003$), were also statistically correlated with HCV susceptibility. Based on these results, we further tested the heterogeneity of each stratified variable and found that no heterogeneity existed between the sub-layers (all $P > 0.05$).
Table 3
Stratified analysis the association of rs34562254 with HCV susceptibility

| Subgroups       | Group A n (CC/CT/TT) | Group B n (CC/CT/TT) | Group C n (CC/CT/TT) | OR(95%CI)\(^a\) | \(P\) \(^a\) | \(P\) \(^b\) |
|-----------------|----------------------|----------------------|----------------------|------------------|-------------|-------------|
| Age             |                      |                      |                      |                  |             |             |
| < 50            | 221/232/78           | 78/99/35             | 131/122/56           | 1.17(0.97–1.41)  | 0.100       |             |
| \(\geq\) 50    | 440/441/92           | 112/152/44           | 181/218/50           | 1.26(1.07–1.66)  | 0.005       |             |
| Gender          |                      |                      |                      |                  |             |             |
| Male            | 234/290/73           | 63/103/33            | 122/108/42           | 1.07(0.89–1.31)  | 0.439       |             |
| Female          | 427/383/97           | 127/148/46           | 190/232/64           | 1.32(1.12–1.55)  | 0.001       |             |
| ALT (U/L)       |                      |                      |                      |                  |             |             |
| \(\leq\) 40    | 622/635/162          | 155/203/57           | 181/194/71           | 1.20(1.06–1.37)  | 0.004       |             |
| > 40            | 33/36/8              | 35/48/21             | 130/145/35           | 1.13(0.78–1.62)  | 0.505       |             |
| AST (U/L)       |                      |                      |                      |                  |             |             |
| \(\leq\) 40    | 624/636/160          | 160/201/58           | 174/202/71           | 1.22(1.07–1.39)  | 0.002       |             |
| > 40            | 30/35/10             | 26/47/19             | 131/136/33           | 1.01(0.68–1.51)  | 0.950       |             |
| Route of infection |                  |                      |                      |                  |             |             |
| HD              | 229/231/75           | 29/47/15             | 41/23/12             | 1.14(0.87–1.49)  | 0.357       |             |
| IVDU            | 77/78/22             | 53/72/23             | 57/59/24             | 1.18(0.89–1.55)  | 0.250       |             |
| PBD             | 355/364/73           | 108/132/41           | 214/258/70           | 1.29(1.09–1.53)  | 0.003       |             |

Abbreviations: CI, confidence interval; HCV, hepatitis C virus; OR, odds ratio; HD, hemodialysis patients; IVDU, Intravenous drug user; PBD, paid blood donors.

Group A: uninfected controls; Group B: spontaneous clearance subjects; Group C: chronic infection patients. Group (B + C): Infected individuals (spontaneous clearance subjects + chronic infection patients).

\(^a\) The \(P\) value, OR and 95% CIs of Group (B + C) versus Group A were calculated on the basis of the additive model, adjusted by gender, age, ALT level, AST level and route of infection.

\(^b\) \(P\) value for the heterogeneity test.

In silico analysis

As shown in Fig. 1, rs34562254 had a RegulomeDB score of 3a, suggesting that it may be located at the transcription factor (TF) binding site, motif, and DNase peak. We used RNAfoldweb servers to predict...
TNFRSF13B RNA secondary structure. The MAF of the centroid secondary structure was higher for the mutant rs34562254 T allele (-38.90 kcal/mol) than its wildtype C allele (-45.60 kcal/mol), indicating that the rs34562254 polymorphism in TNFRSF13B could affect the transcription of related RNA (Fig. 1). We also explored the potential biological functions of rs34562254 in the Encyclopedia of DNA Elements (ENCODE) project using the UCSC genome browser. As shown in Fig. 2, rs34562254 was located on the highest peak of the H3K4Me1 histone marker in seven cell lines. H3K4me1 is a major histone modification associated with enhancer elements in nucleosomes and is linked to the transcriptional regulation of genes.

Discussion

We found that TNFRSF13B rs34562254 was associated with HCV infection susceptibility. More specifically, compared to subjects with rs34562254-CC (the wild type), those with CT/TT have an increased risk of HCV infection. The T allele's effect was stronger in subjects who were older (≥ 50 years old), female, PBDs, and those with lower ALT and AST levels (≤ 40 U/L). Moreover, our bioinformatics analysis found that rs34562254 was located at the highest peak of the H3K4Me1 histone marker and potentially regulates mRNA transcription by affecting TF binding.

TNFRSF13B is a lymphocyte-specific tumor necrosis factor receptor that interacts with the NF-κB pathway and regulates B-cell development [28, 29]. It has been reported to be associated with a variety of human immune-related diseases such as CVID [22], asthma [24], and SLE [23]. Furthermore, Rand et al. have found that the TNFRSF13B rs34562254 polymorphism was correlated with multiple myeloma and coronary artery lesions [30]. In this study, based on the analyses of four genetic markers, we found that subjects with rs34562254-T were associated with an elevated risk of HCV infection.

From the NCBI dbSNP browser (https://www.ncbi.nlm.nih.gov/snp/), we found that rs34562254 is a missense mutation located in the exon region of TNFRSF13B. According to RegulomeDB, its RegulomeDB score is 3a (https://www.regulomedb.org/regulome-search/?regions=rs34562254&genome=GRCh37). RegulomeDB is a database that links SNPs with known and predicted regulatory elements within the intergenic regions of the Homo sapiens genome. The RegulomeDB score represents a model integrating functional genomics features with continuous values such as the expression of quantitative trait loci, TF binding, TF motif, ChIP-seq signal, and DNase Footprint [31]. Therefore, the rs34562254 SNP might have transcriptional regulatory functions including TF binding and DNase peak. Through the RNAfold web server, we found that the wildtype C allele of the centroid secondary structure had a lower MFE than the mutant T allele (-45.60 versus −38.90 kcal/mol). From the ENCODE project and the UCSC genome browser, we found that rs34562254 was located on the highest peak of the H3K4Me1 histone marker, a major histone modification around enhancer elements in nucleosomes. When enhancer regions are enriched with H3K4me1 modifications, the enhancer enters a state of equilibrium. In contrast, when enhancer regions become enriched with both H3K4me1 and H3K27ac modifications, the enhancer enters an activated state that promotes gene expression [32]. Consequently, we speculate that genetic variants in rs34562254 might affect TNFRSF13B expression by influencing TF binding.
The stratified analysis showed that the rs34562254-T allele was significantly associated with HCV susceptibility in subjects that were female, over 50 years old, PBDs, and that had reduced ALT and AST levels ($\leq 40$ U/L). In general, compared to men, women usually develop more intense innate, humoral, and cellular immune responses to viral infections and vaccinations\[33\], suggesting that the allele's associated risk is more significant in females. ALT and AST level are major indicators of liver injury severity. In hepatitis C, ALT and AST levels become abnormal ($> 40$ U/L), which may confound the effects of the rs34562254-T allele\[19\]. HCV is a common infection among older adults in certain areas of China\[34\]. Generally, older people are less healthy and are more likely than younger people to be exposed to potentially contaminated needles or blood products\[35\]. Accordingly, our result showed that the risk effect of the allele was more significant in the over 50 years old subgroup. For PBDs, they may rely on blood donation as a source of income. Blood-borne diseases such as HCV and HIV were frequently detected among PBDs in China during the early 1980s\[36\]; HCV infection was very prevalent\[37\].

Several limitations exist in this study. First, we did not test other SNPs in TNFSF/TNFRSF that may associate with HCV infection. Therefore, additional studies with more extensive genomic coverage are required to increase understanding of the role of TNFRSF13B polymorphisms in HCV infection. Second, in the multivariate regression analysis of TNFRSF SNP distribution and HCV infection outcome, HCV genotypes were not included due to a lack of data. Instead, we used existing HCV genotype data to perform a logistic regression on rs34562254 and found that the $P$ value did not change. In future studies, we will collect as much baseline data as possible to improve our reliability. Finally, the potential biological functions of TNFRSF13B rs34562254 were speculated in the in silico analysis. The exact mechanisms of rs34562254 in TNFRSF13B in HCV infection need to be further investigated.

Conclusions

This study was the first to report that the TNFRSF13B missense mutation rs34562254 was significantly associated with HCV susceptibility among the Han Chinese population. Moreover, the increased risk of the mutant genotype was stronger in subjects who were females, older ($\geq 50$ years old), PBDs, and who had lower ALT and AST levels ($\leq 40$ U/L). These findings are valuable in deepening the understanding of HCV infection susceptibility and offer a reference to develop prevention and control strategies among populations at high risk of repeated HCV infections.

Abbreviations

TNFRSF: tumor necrosis factor receptor superfamily; TNFSF: tumor necrosis factor superfamily; HCV: hepatitis C virus; HCC: hepatic carcinoma; DAAs: direct-acting antivirals; RA: rheumatoid arthritis; IBD: inflammatory bowel disease; MS: multiple sclerosis; CLL: chronic lymphocytic leukemia; SLE: systemic lupus erythematosus; CVID: common variable immunodeficiency; SNPs: single nucleotide polymorphisms; IVDU: Intravenous drug users; HD: hemodialysis patients; PBD: paid blood donors; HIV: human immunodeficiency virus; HBV: hepatitis B virus; ALT: alanine aminotransferase; AST: aspartate aminotransferase; MAF: minor allele frequency; HWE: Hardy-Weinberg equilibrium; ANOVA: one-way
analysis of variance; ORs: odds ratios; CI: confidence intervals; GWAS: genome-wide association study; TACI: transmembrane activator and CAML interactor; SAE: serious adverse event; TN: treatment-naïve; TE: treatment-experienced; WHO: World Health Organization.

Declarations

Ethics approval and consent to participate

All study procedures were approved by the medical ethics committee of Nanjing Medical University in accordance with the Declaration of Helsinki. The written informed consent was obtained from each participant.

Consent of publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

The current study was financially supported by the National Natural Science Foundation of China (Grant No. 81773499), Science Foundation for Distinguished Young Scholars of Jiangsu Province (Grant No. BK20190106), Open Research Fund Program of the State Key Laboratory of Virology of China (Grant No. 2019KF005), Key Project of Natural Science Foundation of Yunnan Province (Grant No. 2019FA005) and Jiangsu Program for Young Medical Talents (Grant No. QNRC2016616)

Authors’ contributions

All authors made substantial contributions to editing and drafting of the manuscript. H.Z.F, Z.Q.F. and M.Y. designed and organized the study and supervised the whole project. H.Z.F, Z.Q.F., Z.J.G., C.H.W., J.L. and M.Y. contributed to field survey, data collection, laboratory detection and quality control. H.Z.F, Z.Q.F., D.C., C.S. and R.B.Y. performed data cleansing and statistical analysis. H.Z.F, Z.Q.F and Y.Z. provided analysis tools and performed data interpretation. H.Z.F., Z.Q.F., C.D. and M.Y. wrote and critical revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors wish to thank Peng Huang, Yan Wang, Xiangyu Ye, Zeyang Ni and Yuqing Hou, for all the contributions to make this study carried out.

References

1. WHO. Global hepatitis report. Geneva World Health Organization. 2017
   http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1[J].
2. Agner KJ. Principles for automation of quantitative chemical analysis by a discontinuous flow system and their application[J]. Scandinavian journal of clinical and laboratory investigation Supplementum, 1967,100(139).
3. Chinese Society of Hepatology and Chinese Society of Infectious Diseases CMA. Guidelines for the prevention and treatment of hepatitis C (2019 version)[J]. J Clin Hepatol, 2019, 35(12):1–17.
4. Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis C virus infection[J]. Ther Adv Infect Dis. 2016;3(1):3–14.
5. Allison RD, Tong X, Moorman AC, et al. Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006–2010[J]. J Hepatol, 2015, 63(4):822–8.
6. Honegger JR, Zhou Y, Walker CM. Will there be a vaccine to prevent HCV infection?[J]. Semin Liver Dis, 2014, 34(1):79–88.
7. WHO. GUIDELINES FOR THE CARE AND TREATMENT OF PERSONS. DIAGNOSED WITH CHRONIC HEPATITIS C VIRUS INFECTION[J]. 2018.
8. Grebely J, Dore GJ, Kim AY, et al. Genetics of spontaneous clearance of hepatitis C virus infection: a complex topic with much to learn[J]. Hepatology, 2014, 60(6):2127-8.
9. Larrubia JR, Moreno-Cubero E, Lokhande MU, et al. Adaptive immune response during hepatitis C virus infection[J]. World J Gastroenterol. 2014;20(13):3418–30.
10. Piconese S, Cammarata I, Barnaba V. Viral hepatitis, inflammation, and cancer: A lesson for autoimmunity[J]. J Autoimmun. 2018;95:58–68.
11. Fletcher NF, Sutaria R, Jo J, et al. Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner[J]. Hepatology, 2014, 59(4):1320–30.
12. Fletcher NF, Clark AR, Balfe P, McKeating JA. TNF superfamily members promote hepatitis C virus entry via an NF-kappaB and myosin light chain kinase dependent pathway[J]. J Gen Virol, 2017, 98(3):405–12.
13. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword[J]. Nat Rev Immunol, 2003, 3(9):745–56.
14. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40[J]. Science. 1993;261(5126):1328–30.
15. Hikosaka Y, Nitta T, Ohigashi I, et al. The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator[J]. Immunity, 2008, 29(3):438–50.
16. Volpe E, Sambucci M, Battistini L, Borsellino G. Fas-Fas Ligand: Checkpoint of T Cell Functions in Multiple Sclerosis[J]. Front Immunol, 2016, 7(382).
17. Yue M, Huang P, Wang C, et al. Genetic Variation on TNF/LTA and TNFRSF1A Genes is Associated with Outcomes of Hepatitis C Virus Infection[J]. Immunol Invest, 2020:1–11.
18. Tian T, Huang P, Wu J, et al. CD40 polymorphisms were associated with HCV infection susceptibility among Chinese population[J]. BMC Infect Dis. 2019;19(1):840.
19. Huang P, Wang CH, Zhuo LY, et al. Polymorphisms rs763110 in FASL is linked to hepatitis C virus infection among high-risk populations[J]. Br J Biomed Sci. 2020;77(3):112–7.
20. Wu JJ, Huang P, Yue M, et al. Association between TNFRSF11A and TNFRSF11B gene polymorphisms and the outcome of hepatitis C virus infection[J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2019, 40(10):1291–5.
21. Enjuanes A, Benavente Y, Bosch F, et al. Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia[J]. Cancer Res, 2008, 68(24):10178–86.
22. Karaca NE, Severcan EU, Guven B, Azarsiz E, Aksu G, Kutukcu N. TNFRSF13B/TACI Alterations in Turkish Patients with Common Variable Immunodeficiency and IgA Deficiency[J]. Avicenna J Med Biotechnol. 2018;10(3):192–5.
23. Wen L, Zhu C, Zhu Z, et al. Exome-wide association study identifies four novel loci for systemic lupus erythematosus in Han Chinese population[J]. 2018, 77(3):417.
24. Janzi M, Melén E, Kull I, Wickman M, Hammarström L. Rare mutations in TNFRSF13B increase the risk of asthma symptoms in Swedish children[J]. Genes Immun. 2012;13(1):59–65.
25. Freiberger T, Ravcukova B, Grodecka L, et al. Sequence variants of the TNFRSF13B gene in Czech CVID and IgAD patients in the context of other populations[J]. Hum Immunol. 2012; 73(11):1147–54.
26. Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis. C[J]. Lancet, 2019, 394(10207):1451–66.
27. Chinese Society of Hepatology and Chinese Society of Infectious Disease CMA. Guidelines for the prevention and treatment of hepatitis C (2019 version)[J]. Journal of Clinical Hepatology, 2019, 35(12):2670–86.
28. Xia XZ, Treanor J, Senaldi G, et al. TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation[J]. J Exp Med. 2000;192(1):137–43.
29. Zhang X, Park CS, Yoon SO, et al. BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors[J]. Int Immunol, 2005, 17(6):779–88.
30. Rand KA, Song C, Dean E, et al. A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci[J]. Cancer Epidemiol Biomarkers Prev. 2016;25(12):1609–18.
31. Dong S, Boyle AP. Predicting functional variants in enhancer and promoter elements using RegulomeDB[J]. Hum Mutat, 2019, 40(9):1292–8.
32. Tian Y, Jia Z, Wang J, et al. Global mapping of H3K4me1 and H3K4me3 reveals the chromatin state-based cell type-specific gene regulation in human Treg cells[J]. PLoS One. 2011;6(11):e27770.
33. Fish EN. The X-files in immunity: sex-based differences predispose immune responses[J]. Nat Rev Immunol, 2008, 8(9): 737–44.

34. Zhang M, Sun XD, Mark SD, et al. Hepatitis C virus infection, Linxian, China[J]. Emerg Infect Dis, 2005, 11(1): 17–21.

35. He J, Lin J. HCV prevalence during the age range of peak sexual activity[J]. Lancet Infect Dis, 2017, 17(2): 131–2.

36. Shan H, Wang JX, Ren FR, et al. Blood banking in China[J]. Lancet, 2002, 360(9347): 1770–5.

37. Rao HY, Sun DG, Yang RF, et al. Outcome of hepatitis C virus infection in Chinese paid plasma donors: a 12-19-year cohort study[J]. J Gastroenterol Hepatol. 2012; 27(3): 526–32.